Argus increased its price target on United Therapeutics as the firm expects the company's Tyvaso and Adcirca drugs to grow fast than its Remodulin treatment. All three drugs treat pulmonary arterial hypertension. Argus predicts that Tyvaso's sales will reach a $400M run rate by 2014. The firm keeps a Buy rating on the shares.
- Health Care Industry
- United Therapeutics